Jiuzhaigou Natural Pharmaceutical Co., Ltd.
Jiuzhaigou Natural Pharmaceutical Co., Ltd. is a national designated manufacturer of national national medicines, a science and technology innovation enterprise in Sichuan Province, and is currently a wholly-owned subsidiary of Sichuan Fengchun Pharmaceutical Group. Jiuyao’s predecessor was Aba Prefecture Pharmaceutical Factory in Sichuan Province. It was founded in 1970. Over the years, the company has based on resource advantages and relying on technological progress, and its scale and strength have been continuously growing. The company makes full use of the unique medicinal resources of "Snow Mountain Grassland" to develop and produce 59 Chinese and Tibetan patent medicines and Western medicines in 11 dosage forms. Varieties such as "獐子子" and "Jiuzhaigou" brand Xiaojin Wan, Xihuang Wan, Niuhuang Xingxiao Wan have won various awards from the state and provincial levels. Chuanbei Sydney Pear Paste, Wuwei Musk Pills, Xiao Chaihu Tablets, and Lianpu Shuangqing Tablets have successively been followed. It was rated as a national protected variety of traditional Chinese medicine; the company was shortlisted in the top 30 large-scale pharmaceutical industry enterprises in Sichuan in 1997, with a large market share of the top 30, etc. In 2008, the company's Yingxiu production base was destroyed during the "May 12" Wenchuan earthquake. Jiuyao people rushed to produce and save themselves in the face of disasters and grief. At present, the Xuankou production base and Jiuyao Deyang Branch have been built.
Jiuzhaigou Natural Pharmaceutical Co., Ltd.
Jiuzhaigou Natural Pharmaceutical Co., Ltd. is a national designated manufacturer of national national medicines, a science and technology innovation enterprise in Sichuan Province, and is currently a wholly-owned subsidiary of Sichuan Fengchun Pharmaceutical Group. Jiuyao’s predecessor was Aba Prefecture Pharmaceutical Factory in Sichuan Province. It was founded in 1970. Over the years, the company has based on resource advantages and relying on technological progress, and its scale and strength have been continuously growing. The company makes full use of the unique medicinal resources of "Snow Mountain Grassland" to develop and produce 59 Chinese and Tibetan patent medicines and Western medicines in 11 dosage forms. Varieties such as "獐子子" and "Jiuzhaigou" brand Xiaojin Wan, Xihuang Wan, Niuhuang Xingxiao Wan have won various awards from the state and provincial levels. Chuanbei Sydney Pear Paste, Wuwei Musk Pills, Xiao Chaihu Tablets, and Lianpu Shuangqing Tablets have successively been followed. It was rated as a national protected variety of traditional Chinese medicine; the company was shortlisted in the top 30 large-scale pharmaceutical industry enterprises in Sichuan in 1997, with a large market share of the top 30, etc. In 2008, the company's Yingxiu production base was destroyed during the "May 12" Wenchuan earthquake. Jiuyao people rushed to produce and save themselves in the face of disasters and grief. At present, the Xuankou production base and Jiuyao Deyang Branch have been built.
Lunan Pharmaceutical Group Co., Ltd.
Lunan Pharmaceutical Group is a comprehensive pharmaceutical group that integrates the production, scientific research and sales of pharmaceuticals, chemical drugs and biological products. It is a national innovative enterprise and a key high-tech enterprise of the National Torch Plan. Member enterprises include Lunan Houpu Pharmaceutical Co., Ltd. Lunan Bet Pharmaceutical Co., Ltd., Shandong New Times Pharmaceutical Co., Ltd., Lunan New Times Pharmaceutical Co., Ltd., etc. Lunan Pharmaceutical Group has multiple high-level R&D platforms, including the National Chiral Pharmaceutical Engineering Technology Research Center, the National Engineering Laboratory for High-efficiency Expression of Mammalian Cells, the National Key Laboratory for Integration of Traditional Chinese Medicine and Modern Traditional Chinese Medicine, and the National Accredited Enterprise Technology Center, and More than 100 universities and research institutes at home and abroad have established technical cooperation, and the enterprise's technology center innovation capabilities rank among the forefront of the national pharmaceutical industry. The company has established a quality assurance system that is in line with international quality supervision concepts such as ICH, FDA, and EDQM. All dosage forms and varieties have passed the national new version of GMP certification. The company has always adhered to the business purpose of "benefiting society and creating a better life", adhered to the corporate spirit of "not afraid of difficulties, challenge difficulties, and overcome difficulties", and adhered to the development strategy of "reform as the driving force, market as the center, and technology as the leader" , has now developed into a national large-scale comprehensive pharmaceutical group, and has been awarded the titles of "National May 1st Labor Certificate", "National Model Workers' Home", and "National Advanced Unit for Mass Sports". Committed to creating an international century-old national pharmaceutical brand and making greater contributions to achieving the goal of "Healthy China, Healthy World". Through the "Workplace Health Class" titled CCTV Finance Channel and "Healthy Shandong" from Shandong Radio and Television News Channel , Phoenix TV's "Phoenix Health" and other columns use multiple channels and platforms to improve the health literacy of the whole people, strengthen health education, and inject the concepts of "preventing before illness" and "treating before illness" into health education. In 2017, Lunan Pharmaceutical Group signed a contract with CCTV to become the "CCTV Health Charity Partner".
Lunan Pharmaceutical Group Co., Ltd.
Lunan Pharmaceutical Group is a comprehensive pharmaceutical group that integrates the production, scientific research and sales of pharmaceuticals, chemical drugs and biological products. It is a national innovative enterprise and a key high-tech enterprise of the National Torch Plan. Member enterprises include Lunan Houpu Pharmaceutical Co., Ltd. Lunan Bet Pharmaceutical Co., Ltd., Shandong New Times Pharmaceutical Co., Ltd., Lunan New Times Pharmaceutical Co., Ltd., etc. Lunan Pharmaceutical Group has multiple high-level R&D platforms, including the National Chiral Pharmaceutical Engineering Technology Research Center, the National Engineering Laboratory for High-efficiency Expression of Mammalian Cells, the National Key Laboratory for Integration of Traditional Chinese Medicine and Modern Traditional Chinese Medicine, and the National Accredited Enterprise Technology Center, and More than 100 universities and research institutes at home and abroad have established technical cooperation, and the enterprise's technology center innovation capabilities rank among the forefront of the national pharmaceutical industry. The company has established a quality assurance system that is in line with international quality supervision concepts such as ICH, FDA, and EDQM. All dosage forms and varieties have passed the national new version of GMP certification. The company has always adhered to the business purpose of "benefiting society and creating a better life", adhered to the corporate spirit of "not afraid of difficulties, challenge difficulties, and overcome difficulties", and adhered to the development strategy of "reform as the driving force, market as the center, and technology as the leader" , has now developed into a national large-scale comprehensive pharmaceutical group, and has been awarded the titles of "National May 1st Labor Certificate", "National Model Workers' Home", and "National Advanced Unit for Mass Sports". Committed to creating an international century-old national pharmaceutical brand and making greater contributions to achieving the goal of "Healthy China, Healthy World". Through the "Workplace Health Class" titled CCTV Finance Channel and "Healthy Shandong" from Shandong Radio and Television News Channel , Phoenix TV's "Phoenix Health" and other columns use multiple channels and platforms to improve the health literacy of the whole people, strengthen health education, and inject the concepts of "preventing before illness" and "treating before illness" into health education. In 2017, Lunan Pharmaceutical Group signed a contract with CCTV to become the "CCTV Health Charity Partner".
Chongqing Hillan Pharmaceutical Co., Ltd.
Chongqing Xier'an Pharmaceutical Co., Ltd. originated in the 37th year of the Kangxi reign (1698 AD). At that time, the Tai Scholar Wu Hongxian created the "Wu Shu Fragrance Room" at the entrance of Taipingmen Fish Market on the Yuzhou Peninsula in ancient Chongqing. Business has been booming for hundreds of years and Debu is the whole country. The traditional production techniques of Wu Shufang plaster are an intangible cultural heritage in Chongqing, and Xier'an Pharmaceutical is a demonstration production base for intangible cultural heritage in Chongqing. Xieran Pharmaceutical has always adhered to the corporate philosophy of "democracy and medicine to benefit the people", adhered to the corporate goal of "building a 10 billion pharmaceutical company, and shaping the top ten traditional Chinese medicine brands Wu Shufang". Now it has developed into a comprehensive R&D, A comprehensive pharmaceutical company integrating production and sales. The company's total assets are nearly 2 billion yuan. The company has been rated as a national key high-tech enterprise, a leading enterprise in the national biological industry base, and a national key leading enterprise in agricultural industrialization. Xier'an Production Base is located in Hechuan Industrial Park, Chongqing, covering an area of more than 500 mu. In recent years, the company has vigorously promoted the construction of intelligent manufacturing, realizing intelligent production integration, data integration, equipment intelligence, and production management intelligence. 16 dosage forms and one drug substance passed the GMP compliance test. The company has rich product resources and has 204 production approval documents. The company vigorously implements the marketing strategy of "building the foundation, increasing thickness; wide coverage, and deepening cultivation". The sales network covers all other provinces, municipalities and autonomous regions in China except Hong Kong, Macao, Taiwan and Tibet, as well as Southeast Asia, Europe, America and other parts. Overseas markets have formed a sales pattern of in-depth cultivation from provincial capital city comprehensive hospitals to district and county health centers, individual clinics, and retail pharmacies, and are committed to creating a number of product lines with competitive advantages such as orthopedics, pediatrics, and dermatology. The company's 83 varieties are included in the "National Basic Medical Insurance Drug Catalog"; 29 varieties are included in the "National Basic Medical Catalog"; and 3 national traditional Chinese medicine protected varieties. The company's key varieties such as Xiaole Huanglong Granules, Jinchan Anti-Itch Capsules, Musk Wind-Chasing Pain Relieving Pain, Qili Tablets, etc. are all exclusive or patented products. They have won the National, Provincial and Municipal Science and Technology Progress Award, Chongqing Major New Products, Chongqing City's high-tech products and other honors. The company adheres to the scientific research strategy of "scientific and technological service to mankind, innovation promotes development", uses science and technology as a means, adheres to the scientific research policy of "combining imitation and creation, paying equal attention to drug and big health products", screening, developing and reserveing a batch of products. R&D pattern. The company's major shareholders invested in the establishment of two R&D institutions - Chongqing Cisco Pharmaceutical Research and Development Co., Ltd. and Chongqing Kerun Biopharmaceutical Research and Development Co., Ltd., which are the national enterprise technology center and the national major science and technology special project "major new drug creation" yeast recombinant protein drug trial Amplification technology platform, Chongqing Engineering Research Center for Recombinant Protein Drugs, Chongqing Postdoctoral Research Workstation, Chongqing Traditional Chinese Medicine Preparation Process Engineering Technology Research Center, Chongqing Traditional Chinese Medicine Rubber Paste Chongqing Key Laboratory of Industry and Information Technology. Xier'an actively explores the mechanism of joint school-running, joint construction of schools and enterprises and integration of industry and education, jointly builds the "Bio-medical Collaborative Innovation Center", promotes scientific and technological exchanges and cooperation between universities, research institutes and enterprises, complements each other's strengths, and strengthens the transformation of innovative achievements. With first-class domestic and foreign scientific research institutes, universities and medical experts as technical support, Xier'an has organized a huge external brain network to carry out extensive industry-university research. The cooperative units include: Chinese Academy of Traditional Chinese Medicine, Chinese Academy of Military Medical Sciences, Beijing University of Traditional Chinese Medicine, Georgia Institute of Technology, West China Medical University, Chengdu University of Traditional Chinese Medicine, Chongqing Medical University, Third Military Medical University, and Chongqing Institute of Traditional Chinese Medicine.
Chongqing Hillan Pharmaceutical Co., Ltd.
Chongqing Xier'an Pharmaceutical Co., Ltd. originated in the 37th year of the Kangxi reign (1698 AD). At that time, the Tai Scholar Wu Hongxian created the "Wu Shu Fragrance Room" at the entrance of Taipingmen Fish Market on the Yuzhou Peninsula in ancient Chongqing. Business has been booming for hundreds of years and Debu is the whole country. The traditional production techniques of Wu Shufang plaster are an intangible cultural heritage in Chongqing, and Xier'an Pharmaceutical is a demonstration production base for intangible cultural heritage in Chongqing. Xieran Pharmaceutical has always adhered to the corporate philosophy of "democracy and medicine to benefit the people", adhered to the corporate goal of "building a 10 billion pharmaceutical company, and shaping the top ten traditional Chinese medicine brands Wu Shufang". Now it has developed into a comprehensive R&D, A comprehensive pharmaceutical company integrating production and sales. The company's total assets are nearly 2 billion yuan. The company has been rated as a national key high-tech enterprise, a leading enterprise in the national biological industry base, and a national key leading enterprise in agricultural industrialization. Xier'an Production Base is located in Hechuan Industrial Park, Chongqing, covering an area of more than 500 mu. In recent years, the company has vigorously promoted the construction of intelligent manufacturing, realizing intelligent production integration, data integration, equipment intelligence, and production management intelligence. 16 dosage forms and one drug substance passed the GMP compliance test. The company has rich product resources and has 204 production approval documents. The company vigorously implements the marketing strategy of "building the foundation, increasing thickness; wide coverage, and deepening cultivation". The sales network covers all other provinces, municipalities and autonomous regions in China except Hong Kong, Macao, Taiwan and Tibet, as well as Southeast Asia, Europe, America and other parts. Overseas markets have formed a sales pattern of in-depth cultivation from provincial capital city comprehensive hospitals to district and county health centers, individual clinics, and retail pharmacies, and are committed to creating a number of product lines with competitive advantages such as orthopedics, pediatrics, and dermatology. The company's 83 varieties are included in the "National Basic Medical Insurance Drug Catalog"; 29 varieties are included in the "National Basic Medical Catalog"; and 3 national traditional Chinese medicine protected varieties. The company's key varieties such as Xiaole Huanglong Granules, Jinchan Anti-Itch Capsules, Musk Wind-Chasing Pain Relieving Pain, Qili Tablets, etc. are all exclusive or patented products. They have won the National, Provincial and Municipal Science and Technology Progress Award, Chongqing Major New Products, Chongqing City's high-tech products and other honors. The company adheres to the scientific research strategy of "scientific and technological service to mankind, innovation promotes development", uses science and technology as a means, adheres to the scientific research policy of "combining imitation and creation, paying equal attention to drug and big health products", screening, developing and reserveing a batch of products. R&D pattern. The company's major shareholders invested in the establishment of two R&D institutions - Chongqing Cisco Pharmaceutical Research and Development Co., Ltd. and Chongqing Kerun Biopharmaceutical Research and Development Co., Ltd., which are the national enterprise technology center and the national major science and technology special project "major new drug creation" yeast recombinant protein drug trial Amplification technology platform, Chongqing Engineering Research Center for Recombinant Protein Drugs, Chongqing Postdoctoral Research Workstation, Chongqing Traditional Chinese Medicine Preparation Process Engineering Technology Research Center, Chongqing Traditional Chinese Medicine Rubber Paste Chongqing Key Laboratory of Industry and Information Technology. Xier'an actively explores the mechanism of joint school-running, joint construction of schools and enterprises and integration of industry and education, jointly builds the "Bio-medical Collaborative Innovation Center", promotes scientific and technological exchanges and cooperation between universities, research institutes and enterprises, complements each other's strengths, and strengthens the transformation of innovative achievements. With first-class domestic and foreign scientific research institutes, universities and medical experts as technical support, Xier'an has organized a huge external brain network to carry out extensive industry-university research. The cooperative units include: Chinese Academy of Traditional Chinese Medicine, Chinese Academy of Military Medical Sciences, Beijing University of Traditional Chinese Medicine, Georgia Institute of Technology, West China Medical University, Chengdu University of Traditional Chinese Medicine, Chongqing Medical University, Third Military Medical University, and Chongqing Institute of Traditional Chinese Medicine.
Hubei Wushi Pharmaceutical Co., Ltd.
Hubei Wushi Pharmaceutical Co., Ltd. was founded in June 1970 and was originally named Anlu Pharmaceutical Factory. In 1997, it was renamed Hubei Wushi Pharmaceutical Co., Ltd. after joint-stock transformation. The company has fixed assets of 240 million yuan, a modern production base of 120,000 square meters and a strong production capacity of Chinese and Western medicines. There are 750 main equipment (sets), more than 1,600 employees, and various professional and technical personnel account for 38% of the company's total number of employees. So far, 144 drug production approval documents and 12 national new drug certificates have been obtained. The company is committed to developing the pharmaceutical industry, taking the path of combining traditional Chinese medicine with modern Western medicine. In 2015, it passed the new version of the GMP certification of the State Food and Drug Administration in one go. It has the production of granules, syrups, pills and tablets. More than ten dosage form capabilities such as , dew agent, mixture, oral liquid, lyophilized powder injection, and chondrial agent. "Kingang Vine Syrup", "Liangyuan Loquat Leaf Paste", "Fitness Changchun Paste" and other products have been rated as "National Traditional Chinese Medicine" Protected varieties", and "Longqi Granules" obtained the national new drug certificate in 2009, which is a complete independent intellectual property rights for our company. Wushi Pharmaceutical is a leading enterprise in the domestic honeysuckle industry, accounting for 75% of the national honeysuckle market. It is the developer of Wushi Tea Granules and the drafter of national standards, Wushi Tea Granules, antiviral oral liquid, glucose calcium and zinc oral solution, Phenylglycopherol powder injection is a best-selling variety in the country, and Qiangli loquat granules are medical insurance products.
Hubei Wushi Pharmaceutical Co., Ltd.
Hubei Wushi Pharmaceutical Co., Ltd. was founded in June 1970 and was originally named Anlu Pharmaceutical Factory. In 1997, it was renamed Hubei Wushi Pharmaceutical Co., Ltd. after joint-stock transformation. The company has fixed assets of 240 million yuan, a modern production base of 120,000 square meters and a strong production capacity of Chinese and Western medicines. There are 750 main equipment (sets), more than 1,600 employees, and various professional and technical personnel account for 38% of the company's total number of employees. So far, 144 drug production approval documents and 12 national new drug certificates have been obtained. The company is committed to developing the pharmaceutical industry, taking the path of combining traditional Chinese medicine with modern Western medicine. In 2015, it passed the new version of the GMP certification of the State Food and Drug Administration in one go. It has the production of granules, syrups, pills and tablets. More than ten dosage form capabilities such as , dew agent, mixture, oral liquid, lyophilized powder injection, and chondrial agent. "Kingang Vine Syrup", "Liangyuan Loquat Leaf Paste", "Fitness Changchun Paste" and other products have been rated as "National Traditional Chinese Medicine" Protected varieties", and "Longqi Granules" obtained the national new drug certificate in 2009, which is a complete independent intellectual property rights for our company. Wushi Pharmaceutical is a leading enterprise in the domestic honeysuckle industry, accounting for 75% of the national honeysuckle market. It is the developer of Wushi Tea Granules and the drafter of national standards, Wushi Tea Granules, antiviral oral liquid, glucose calcium and zinc oral solution, Phenylglycopherol powder injection is a best-selling variety in the country, and Qiangli loquat granules are medical insurance products.
Sichuan Rainbow Pharmaceutical Co., Ltd.
Sichuan Rainbow Pharmaceutical Co., Ltd. was established on October 9, 1998. The legal representative is Wu Xiaohong. In 2009, Sichuan Rainbow Pharmaceutical Co., Ltd. added 83.67 mu of land in Qingshen County Industrial Development Zone, Meishan City, and invested 70 million yuan to build new factory buildings and facilities. , equipment, solid preparation workshop, liquid preparation workshop, warehouse, office building, inspection building, seven purification production lines including tablets, capsules, granules, and designed production capacity of 200 million yuan; it is a company that is strictly designed and built in accordance with the standardized "GMP" A modern pharmaceutical company that has passed the new version of GMP certification. 1. Basic information of the company The company's registered capital is 50.25 million yuan, covering an area of 83.67 mu, a total factory area of 24748.86 square meters, total assets are more than 90 million yuan, and more than 50 varieties and specifications. In August 2016, it merged Chengdu Jule Pharmaceutical Co., Ltd. as a whole and added Jule Nine varieties of Shugan Tablets under Le's name have been successfully transferred to the company. Now they have registered more than 350 employees, more than 500 units (sets), and achieved sales revenue of 120 million yuan. 2. Company honors and brand building The company's Shenchai Capsules, Huoka, Xiangzhengqi Water, compound isatis root granules, compound Yinqiao Capsules, etc. are sold in more than 20 provinces and cities across the country. The finished products have established the Rainbow’s “Kangsen” brand effect in China, and have unique advantages among similar manufacturers and have strong market competitiveness. Since the registration of the "Kangsen" trademark, the company has paid special attention to product quality and has achieved no quality and safety accidents or public quality recruitment in the past three years. The company has established extensive academic connections with Sichuan University West China Medical College and Chengdu University of Traditional Chinese Medicine, ensuring the advanced and authoritative technology. At present, the company's Shenchai Capsule Flow Extract and Traditional Chinese Medicine Extraction Heat Reflux Technology and the innovative technology of compound Yinjingammonic Capsules are among the cutting-edge technologies in the domestic industry. 3. Company sales and network construction 1. In terms of market sales and sales network construction, the company has established offices and sales networks in fifteen provinces through ten years, and has sold more than 20 provinces. 2. OTC sales are the company's focus on building and construction. In terms of product positioning, the company positions the entire packaging in a mid-to-high-end position and sets the unit price in a mid-range position. Build a brand in a variety of different ways. With the expectation of increasing prices and increasing added value, an OTC team mainly consisting of Sichuan and Chongqing and covering the national market positioning has been established, with a total of 200 people engaged in it. 4. Foreign investment enterprises Sichuan Rainbow Pharmaceutical Co., Ltd. invested 3 million yuan in 2008 to establish Sichuan Hongsheng Pharmaceutical Packaging Co., Ltd., covering an area of 10 acres. It has two types of medicine packaging materials, namely oral solid medicinal polypropylene bottles and oral liquid medicinal high-density polyethylene bottles. It is certified to produce about 50 bottle types including 10ml, 20ml, 30ml, 40ml, 60ml, 80ml, 100ml, 150ml, 300ml, etc. From the purchase of raw materials to the factory, it is strictly produced and standardized in accordance with GMP requirements. In 2013, Sichuan Hongsheng Pharmaceutical Packaging Co., Ltd. purchased a newly fully automatic grinding and injection molding machine with an output value of 6 million yuan. Sichuan Yuetong Pharmaceutical Co., Ltd. was established in 2010 and is a newly established commercial company that the company has wholly owned.
Sichuan Rainbow Pharmaceutical Co., Ltd.
Sichuan Rainbow Pharmaceutical Co., Ltd. was established on October 9, 1998. The legal representative is Wu Xiaohong. In 2009, Sichuan Rainbow Pharmaceutical Co., Ltd. added 83.67 mu of land in Qingshen County Industrial Development Zone, Meishan City, and invested 70 million yuan to build new factory buildings and facilities. , equipment, solid preparation workshop, liquid preparation workshop, warehouse, office building, inspection building, seven purification production lines including tablets, capsules, granules, and designed production capacity of 200 million yuan; it is a company that is strictly designed and built in accordance with the standardized "GMP" A modern pharmaceutical company that has passed the new version of GMP certification. 1. Basic information of the company The company's registered capital is 50.25 million yuan, covering an area of 83.67 mu, a total factory area of 24748.86 square meters, total assets are more than 90 million yuan, and more than 50 varieties and specifications. In August 2016, it merged Chengdu Jule Pharmaceutical Co., Ltd. as a whole and added Jule Nine varieties of Shugan Tablets under Le's name have been successfully transferred to the company. Now they have registered more than 350 employees, more than 500 units (sets), and achieved sales revenue of 120 million yuan. 2. Company honors and brand building The company's Shenchai Capsules, Huoka, Xiangzhengqi Water, compound isatis root granules, compound Yinqiao Capsules, etc. are sold in more than 20 provinces and cities across the country. The finished products have established the Rainbow’s “Kangsen” brand effect in China, and have unique advantages among similar manufacturers and have strong market competitiveness. Since the registration of the "Kangsen" trademark, the company has paid special attention to product quality and has achieved no quality and safety accidents or public quality recruitment in the past three years. The company has established extensive academic connections with Sichuan University West China Medical College and Chengdu University of Traditional Chinese Medicine, ensuring the advanced and authoritative technology. At present, the company's Shenchai Capsule Flow Extract and Traditional Chinese Medicine Extraction Heat Reflux Technology and the innovative technology of compound Yinjingammonic Capsules are among the cutting-edge technologies in the domestic industry. 3. Company sales and network construction 1. In terms of market sales and sales network construction, the company has established offices and sales networks in fifteen provinces through ten years, and has sold more than 20 provinces. 2. OTC sales are the company's focus on building and construction. In terms of product positioning, the company positions the entire packaging in a mid-to-high-end position and sets the unit price in a mid-range position. Build a brand in a variety of different ways. With the expectation of increasing prices and increasing added value, an OTC team mainly consisting of Sichuan and Chongqing and covering the national market positioning has been established, with a total of 200 people engaged in it. 4. Foreign investment enterprises Sichuan Rainbow Pharmaceutical Co., Ltd. invested 3 million yuan in 2008 to establish Sichuan Hongsheng Pharmaceutical Packaging Co., Ltd., covering an area of 10 acres. It has two types of medicine packaging materials, namely oral solid medicinal polypropylene bottles and oral liquid medicinal high-density polyethylene bottles. It is certified to produce about 50 bottle types including 10ml, 20ml, 30ml, 40ml, 60ml, 80ml, 100ml, 150ml, 300ml, etc. From the purchase of raw materials to the factory, it is strictly produced and standardized in accordance with GMP requirements. In 2013, Sichuan Hongsheng Pharmaceutical Packaging Co., Ltd. purchased a newly fully automatic grinding and injection molding machine with an output value of 6 million yuan. Sichuan Yuetong Pharmaceutical Co., Ltd. was established in 2010 and is a newly established commercial company that the company has wholly owned.
Shandong Kongfu Pharmaceutical Co., Ltd.
Shandong Kongfu Pharmaceutical Co., Ltd. is located in Qufu City, a historical and cultural city and the hometown of Confucius. It is affiliated to Shandong Yulong Mining Group Co., Ltd. It is a key enterprise for Yulong Group to adjust its industrial structure and promote its transformation and development. It is a specialized in the production of Chinese patent medicines and chemical medicines. A technology-intensive modern pharmaceutical enterprise for raw materials and preparation products. The company has existing assets of 80 million yuan, and all production lines passed the national drug GMP certification in November 2008. In 2005, it was recognized as a "high-tech enterprise" by the Provincial Department of Science and Technology. The company's products are mainly made up of traditional Chinese patent medicine OTC products, with seven dosage forms, including oral liquid, syrup, granules, tablets, capsules, pills, and powders, including "Niuhuang Snake Dan Chuanbei Liquid" and "Greatinian Granules "It is a national protected variety of traditional Chinese medicine. The company's traditional Chinese medicine department products are mainly Chinese patent medicine OTC products, with 6 dosage forms and 39 varieties. The leading varieties include beef yellow snake gallbladder Chuanbei liquid, gastritis granules, wind-cold, wind-heat cold granules, orange red granules, Pudilan anti-inflammatory tablets and other products. Yulong Pharmaceutical Industrial Park (Ministry of Chemical Pharmaceuticals), built a high-standard production workshop and laboratory in 2012. In cooperation with Beijing Haibu Pharmaceutical Technology Co., Ltd., it introduced a number of first-line anti-tumor and cardiovascular and cerebrovascular treatments with international advanced levels. Varieties include erlotinib hydrochloride, pitavastatin calcium, and amrisintan. The company actively carries out the transformation of new and old kinetic energy, solidly promotes the construction of key projects, and completes the expansion project of the new oral liquid workshop, the transformation project of oral solid preparation workshop, and the pretreatment and extraction project of traditional Chinese medicine. The company's product sales have spread across the country, and beef yellow snake gallbladder Sichuan shell liquid, wind-cold cold granules, etc. have become well-known regional products. The concept of "pinning the source of the simplicity" and "a medicine of benevolence" and the "Kongfu" brand with a profound Confucian culture have become unique advantages for the long-term development of Kongfu Pharmaceutical.
Shandong Kongfu Pharmaceutical Co., Ltd.
Shandong Kongfu Pharmaceutical Co., Ltd. is located in Qufu City, a historical and cultural city and the hometown of Confucius. It is affiliated to Shandong Yulong Mining Group Co., Ltd. It is a key enterprise for Yulong Group to adjust its industrial structure and promote its transformation and development. It is a specialized in the production of Chinese patent medicines and chemical medicines. A technology-intensive modern pharmaceutical enterprise for raw materials and preparation products. The company has existing assets of 80 million yuan, and all production lines passed the national drug GMP certification in November 2008. In 2005, it was recognized as a "high-tech enterprise" by the Provincial Department of Science and Technology. The company's products are mainly made up of traditional Chinese patent medicine OTC products, with seven dosage forms, including oral liquid, syrup, granules, tablets, capsules, pills, and powders, including "Niuhuang Snake Dan Chuanbei Liquid" and "Greatinian Granules "It is a national protected variety of traditional Chinese medicine. The company's traditional Chinese medicine department products are mainly Chinese patent medicine OTC products, with 6 dosage forms and 39 varieties. The leading varieties include beef yellow snake gallbladder Chuanbei liquid, gastritis granules, wind-cold, wind-heat cold granules, orange red granules, Pudilan anti-inflammatory tablets and other products. Yulong Pharmaceutical Industrial Park (Ministry of Chemical Pharmaceuticals), built a high-standard production workshop and laboratory in 2012. In cooperation with Beijing Haibu Pharmaceutical Technology Co., Ltd., it introduced a number of first-line anti-tumor and cardiovascular and cerebrovascular treatments with international advanced levels. Varieties include erlotinib hydrochloride, pitavastatin calcium, and amrisintan. The company actively carries out the transformation of new and old kinetic energy, solidly promotes the construction of key projects, and completes the expansion project of the new oral liquid workshop, the transformation project of oral solid preparation workshop, and the pretreatment and extraction project of traditional Chinese medicine. The company's product sales have spread across the country, and beef yellow snake gallbladder Sichuan shell liquid, wind-cold cold granules, etc. have become well-known regional products. The concept of "pinning the source of the simplicity" and "a medicine of benevolence" and the "Kongfu" brand with a profound Confucian culture have become unique advantages for the long-term development of Kongfu Pharmaceutical.
Wu Ling Wu Pharmaceutical Co., Ltd.
Wu05 Pharmaceutical Co., Ltd. is a modern high-tech pharmaceutical enterprise invested and built by Wu05 Group. With the mission of defending human health, talent and technology as the two wings, the company continues to promote the modernization of traditional Chinese medicine in the motherland, overcome obstacles and innovate on the road of human medical health. The company introduces pharmaceutical production equipment with world-class advanced level, with high automation, a perfect quality assurance system, and a strong professional R&D team. There are three extraction production lines for Chinese medicinal materials pretreatment, water extraction and alcohol extraction, and four preparation lines for tablets, capsules, granules and lotions. The annual production of 500 million tablets, 300 million capsules, 50 tons of granules, 12 million bottles of lotion. The company currently has more than 20 approved drugs for qualifying sizes approved by the State Food and Drug Administration, and its leading products include 505 Luoyutong Capsules, 505 Shenqi Ginseng Gang Candies, 505 Huangpu Skin Cleansing Lotion, etc. At present, the company has formed its own unique market sales network and opened up a business system with large and medium-sized cities as the dominant market. The existing products have strongest among similar domestic products due to their characteristics such as fast dissolution, good absorption, easy use, and accurate efficacy. market competitive advantage.
Wu Ling Wu Pharmaceutical Co., Ltd.
Wu05 Pharmaceutical Co., Ltd. is a modern high-tech pharmaceutical enterprise invested and built by Wu05 Group. With the mission of defending human health, talent and technology as the two wings, the company continues to promote the modernization of traditional Chinese medicine in the motherland, overcome obstacles and innovate on the road of human medical health. The company introduces pharmaceutical production equipment with world-class advanced level, with high automation, a perfect quality assurance system, and a strong professional R&D team. There are three extraction production lines for Chinese medicinal materials pretreatment, water extraction and alcohol extraction, and four preparation lines for tablets, capsules, granules and lotions. The annual production of 500 million tablets, 300 million capsules, 50 tons of granules, 12 million bottles of lotion. The company currently has more than 20 approved drugs for qualifying sizes approved by the State Food and Drug Administration, and its leading products include 505 Luoyutong Capsules, 505 Shenqi Ginseng Gang Candies, 505 Huangpu Skin Cleansing Lotion, etc. At present, the company has formed its own unique market sales network and opened up a business system with large and medium-sized cities as the dominant market. The existing products have strongest among similar domestic products due to their characteristics such as fast dissolution, good absorption, easy use, and accurate efficacy. market competitive advantage.
Guangxi Wuzhou Pharmaceutical Group
A major Chinese pharmaceutical company specializing in traditional herbal medicines, including Jingfang Granules.
Guangxi Wuzhou Pharmaceutical Group
A major Chinese pharmaceutical company specializing in traditional herbal medicines, including Jingfang Granules.
Kunming Pharmaceutical Corporation
A renowned Chinese pharmaceutical company specializing in traditional herbal medicines, including Jingfang Granules.
Kunming Pharmaceutical Corporation
A renowned Chinese pharmaceutical company specializing in traditional herbal medicines, including Jingfang Granules.
Jiangsu Kanion Pharmaceutical
A prominent Chinese pharmaceutical company producing a range of herbal medicines, including Jingfang Granules.
Jiangsu Kanion Pharmaceutical
A prominent Chinese pharmaceutical company producing a range of herbal medicines, including Jingfang Granules.
Tibet Cheezheng Tibetan Medicine
A prominent Chinese pharmaceutical company offering a variety of herbal products, including Jingfang Granules.
Tibet Cheezheng Tibetan Medicine
A prominent Chinese pharmaceutical company offering a variety of herbal products, including Jingfang Granules.
Shijiazhuang Yiling Pharmaceutical
A leading Chinese pharmaceutical company specializing in traditional herbal medicines, including Jingfang Granules.
Shijiazhuang Yiling Pharmaceutical
A leading Chinese pharmaceutical company specializing in traditional herbal medicines, including Jingfang Granules.
Guizhou Yibai Pharmaceutical
A renowned Chinese pharmaceutical company producing high-quality Jingfang Granules and other herbal remedies.
Guizhou Yibai Pharmaceutical
A renowned Chinese pharmaceutical company producing high-quality Jingfang Granules and other herbal remedies.
Min Tong offers a range of TCM products, including Si Wu Tang, to promote overall health and well-being.
Min Tong Herbal Inc.
Min Tong offers a range of TCM products, including Si Wu Tang, to promote overall health and well-being.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
A renowned brand for traditional Chinese medicines, including donkey-hide gelatin.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
A renowned brand for traditional Chinese medicines, including donkey-hide gelatin.
Tianjin Zhongxin Pharmaceutical Group Co., Ltd.
Specializes in traditional Chinese medicines, including donkey-hide gelatin.
Tianjin Zhongxin Pharmaceutical Group Co., Ltd.
Specializes in traditional Chinese medicines, including donkey-hide gelatin.
Beijing Tong Ren Tang Group
Tong Ren Tang is a centuries-old brand known for its traditional Chinese medicine, including its effective autumn pear syrup.
Beijing Tong Ren Tang Group
Tong Ren Tang is a centuries-old brand known for its traditional Chinese medicine, including its effective autumn pear syrup.
Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai Pharmaceutical Group Co., Ltd. is the only pharmaceutical listed company in China that has a leading position in pharmaceutical products and distribution markets. The company's R&D is based on innovation as its long-term adherence to, and is committed to providing safe and effective therapeutic drugs for major diseases and chronic diseases. In 2012, R&D investment accounted for 4.72% of the company's pharmaceutical business sales revenue. The company has established a research and development system for the branch of the Group General Academy with the Central Research Institute as its technical core, with 1 national-level enterprise technology center and 10 provincial and municipal enterprise technology centers, and has been selected for more than ten major national science and technology projects of "major new drug creation". The company adopts an open research model, established a strategic alliance for innovative drug research and development with the Shanghai Institute of Pharmaceuticals of the Chinese Academy of Sciences, established joint laboratories with China Pharmaceutical University, Shenyang Pharmaceutical University, etc., and cooperated with Japan's Mitsubishi Tanabe Pharmaceutical Co., Ltd. and Shanghai Fudan Zhangjiang Biomedicine to carry out innovative drug research and development; at the same time, it also began to enter the field of therapeutic antibodies through project introduction, cooperative development and other methods. Shanghai pharmaceutical manufacturing covers the fields of chemical and biological medicine, modern Chinese medicine and health products, medical devices, etc. The products focus on five major therapeutic areas: cardiovascular and cerebrovascular, systemic anti-infection, digestive system and immunometabolism, neuropsychiatric, and anti-tumor. It produces more than 20 dosage forms such as tablets, capsules, powder injections (including lyophilized), small-volume injections, eye drops, aerosols, gels, etc., and has over 100 million products. The company's Xinyi, Leishi, Longhu, Qingchunbao, Hu Qingyutang, Cangsong, Guofeng, Shenxiang and other brands are well-known trademarks in China. The company's pharmaceutical production strictly implements China's new version of GMP requirements, and multiple raw materials or preparations have passed the quality certification of WHO, FDA, the EU and other developed countries. Shanghai Pharmaceutical's distribution network radiates across the country with the three key areas of East China, North China and South China, with the most economically developed in China, and ranks second in the country in terms of business scale. The company's distribution business is mainly hospital pure sales, and it cooperates with more than 40 multinational pharmaceutical companies around the world. The company's new businesses such as vaccines, high-end consumables, DTP (direct delivery of high-value drugs) and SPD (pharmaceutical flow management technology) are leading in China. The company's distribution services are gradually moving towards modern hospital service solutions with supply chain extension services and clinical support services as the core, providing hospital customers with terminal solutions, special logistics and information services. Shanghai Pharmaceutical Retail has many well-known brands such as Fahrenheit, Lei Yunshang, Yu Tiancheng, Life Insurance, Leimon, Keyuan Xinhai Pharmacy, etc., covering 12 provinces, municipalities and autonomous regions across the country, with a total of 1,792 stores. In 2012, the company's pharmaceutical retail sales scale ranked among the top five in the national pharmaceutical retail industry, and Shanghai Fahrenheit Pharmacy is the company with the largest number of pharmacies in East China. Shanghai Pharmaceutical's retail business includes chain pharmacies, co-organized pharmacies, DTP pharmacies and other business formats, and actively develops e-commerce to achieve online sales. Shanghai Pharmaceutical advocates the core corporate values of "innovation, integrity, cooperation, inclusiveness, and responsibility", and is committed to perseverance, improving the people's healthy quality of life, and striving to build a leading brand drug manufacturer and health service provider that is respected and has an industry reputation.
Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai Pharmaceutical Group Co., Ltd. is the only pharmaceutical listed company in China that has a leading position in pharmaceutical products and distribution markets. The company's R&D is based on innovation as its long-term adherence to, and is committed to providing safe and effective therapeutic drugs for major diseases and chronic diseases. In 2012, R&D investment accounted for 4.72% of the company's pharmaceutical business sales revenue. The company has established a research and development system for the branch of the Group General Academy with the Central Research Institute as its technical core, with 1 national-level enterprise technology center and 10 provincial and municipal enterprise technology centers, and has been selected for more than ten major national science and technology projects of "major new drug creation". The company adopts an open research model, established a strategic alliance for innovative drug research and development with the Shanghai Institute of Pharmaceuticals of the Chinese Academy of Sciences, established joint laboratories with China Pharmaceutical University, Shenyang Pharmaceutical University, etc., and cooperated with Japan's Mitsubishi Tanabe Pharmaceutical Co., Ltd. and Shanghai Fudan Zhangjiang Biomedicine to carry out innovative drug research and development; at the same time, it also began to enter the field of therapeutic antibodies through project introduction, cooperative development and other methods. Shanghai pharmaceutical manufacturing covers the fields of chemical and biological medicine, modern Chinese medicine and health products, medical devices, etc. The products focus on five major therapeutic areas: cardiovascular and cerebrovascular, systemic anti-infection, digestive system and immunometabolism, neuropsychiatric, and anti-tumor. It produces more than 20 dosage forms such as tablets, capsules, powder injections (including lyophilized), small-volume injections, eye drops, aerosols, gels, etc., and has over 100 million products. The company's Xinyi, Leishi, Longhu, Qingchunbao, Hu Qingyutang, Cangsong, Guofeng, Shenxiang and other brands are well-known trademarks in China. The company's pharmaceutical production strictly implements China's new version of GMP requirements, and multiple raw materials or preparations have passed the quality certification of WHO, FDA, the EU and other developed countries. Shanghai Pharmaceutical's distribution network radiates across the country with the three key areas of East China, North China and South China, with the most economically developed in China, and ranks second in the country in terms of business scale. The company's distribution business is mainly hospital pure sales, and it cooperates with more than 40 multinational pharmaceutical companies around the world. The company's new businesses such as vaccines, high-end consumables, DTP (direct delivery of high-value drugs) and SPD (pharmaceutical flow management technology) are leading in China. The company's distribution services are gradually moving towards modern hospital service solutions with supply chain extension services and clinical support services as the core, providing hospital customers with terminal solutions, special logistics and information services. Shanghai Pharmaceutical Retail has many well-known brands such as Fahrenheit, Lei Yunshang, Yu Tiancheng, Life Insurance, Leimon, Keyuan Xinhai Pharmacy, etc., covering 12 provinces, municipalities and autonomous regions across the country, with a total of 1,792 stores. In 2012, the company's pharmaceutical retail sales scale ranked among the top five in the national pharmaceutical retail industry, and Shanghai Fahrenheit Pharmacy is the company with the largest number of pharmacies in East China. Shanghai Pharmaceutical's retail business includes chain pharmacies, co-organized pharmacies, DTP pharmacies and other business formats, and actively develops e-commerce to achieve online sales. Shanghai Pharmaceutical advocates the core corporate values of "innovation, integrity, cooperation, inclusiveness, and responsibility", and is committed to perseverance, improving the people's healthy quality of life, and striving to build a leading brand drug manufacturer and health service provider that is respected and has an industry reputation.
Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Habin Pharmaceutical Group") is a Sino-foreign joint venture and owns two listed companies, Harbin Pharmaceutical Co., Ltd. and Renmin Tongtai. The group owns the Harbin Pharmaceutical General Factory, Harbin Pharmaceutical Three Essences, Harbin Pharmaceutical Sixth Factory, Harbin Pharmaceutical Two Chinese Medicine Factory, Harbin Pharmaceutical Shiyitang, Harbin Pharmaceutical Biology, Harbin Pharmaceutical Three Essences Factory, Harbin Pharmaceutical Three Essences Factory, Harbin Pharmaceutical Three Essences, Harbin Pharmaceutical Three Es 11 industrial enterprises including He, Harbin Pharmaceutical Sanjing Children, Harbin Pharmaceutical Vaccine, and 2 commercial distribution enterprises and 1 drug research institute, Harbin Pharmaceutical People's Tongtai and Harbin Pharmaceutical Marketing Co., Ltd. The group's main business covers six major business segments: antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, animal vaccines and pharmaceutical business. Harbin Pharmaceutical Co., Ltd. has 1,816 drug approvals and 74 health food approvals. The leading products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, prostadil injection, pediatric aminophen Huangnamin granules, lacidipine tablets, and ceftiam hydrochloride for injection , ibuprofen granules, new gay Zhonggai brand high calcium tablets, etc. As of the end of 2018, it has annually produced 2,200 tons of raw materials, 980 million chemical injections, 180 million traditional Chinese medicine injections, 2 billion oral liquids, 12 billion tablets, 13.1 billion capsules, and 1.2 billion bags of chemical granules. Production capacity. In 2018, the group had 8 varieties with sales revenue of over 100 million yuan, and had five trademarks of "Hayi Medicine", "Three Essences", "Guizhonggu", "Hutong", "Shiyitang" and "Shiyitang" and the use of "Shiyitang". right. Rentongtai, the listed company, mainly engaged in pharmaceutical wholesale and retail businesses, covering more than 10,000 product specifications, including Chinese patent medicines, Chinese herbal medicines, chemical preparations, antibiotics, biological products, biochemical drugs, medical devices and health products. There are 314 Renmin Tongtai Pharmaceutical chain stores with an annual turnover of 1.15 billion yuan. Its drug wholesale enterprises have carried out close cooperation with more than 1,000 medical institutions, more than 1,900 third terminals, and nearly 700 commercial customers in Heilongjiang Province. The market coverage rate of third-level hospitals is more than 95%, and the market coverage of second-level hospitals is more than 2-level hospitals. The rate is more than 90%. Its logistics and distribution center is the first modern medical flow center in Heilongjiang Province and a larger Northeast region. Its storage capacity is 400,000 boxes and an annual throughput capacity of 30 billion yuan. The Group also has a new drug research and development base covering an area of 40,000 square meters and a building area of 38,000 square meters - Harbin Pharmaceutical Group Technology Center, which has five research and developments, including biopharmaceuticals, chemical raw materials, chemical preparations, health foods, and quality testing and analysis. The platform has 25 invention authorized patents, and has obtained 6 production approvals and 17 clinical approvals in the past five years.
Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Habin Pharmaceutical Group") is a Sino-foreign joint venture and owns two listed companies, Harbin Pharmaceutical Co., Ltd. and Renmin Tongtai. The group owns the Harbin Pharmaceutical General Factory, Harbin Pharmaceutical Three Essences, Harbin Pharmaceutical Sixth Factory, Harbin Pharmaceutical Two Chinese Medicine Factory, Harbin Pharmaceutical Shiyitang, Harbin Pharmaceutical Biology, Harbin Pharmaceutical Three Essences Factory, Harbin Pharmaceutical Three Essences Factory, Harbin Pharmaceutical Three Essences, Harbin Pharmaceutical Three Es 11 industrial enterprises including He, Harbin Pharmaceutical Sanjing Children, Harbin Pharmaceutical Vaccine, and 2 commercial distribution enterprises and 1 drug research institute, Harbin Pharmaceutical People's Tongtai and Harbin Pharmaceutical Marketing Co., Ltd. The group's main business covers six major business segments: antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, animal vaccines and pharmaceutical business. Harbin Pharmaceutical Co., Ltd. has 1,816 drug approvals and 74 health food approvals. The leading products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, prostadil injection, pediatric aminophen Huangnamin granules, lacidipine tablets, and ceftiam hydrochloride for injection , ibuprofen granules, new gay Zhonggai brand high calcium tablets, etc. As of the end of 2018, it has annually produced 2,200 tons of raw materials, 980 million chemical injections, 180 million traditional Chinese medicine injections, 2 billion oral liquids, 12 billion tablets, 13.1 billion capsules, and 1.2 billion bags of chemical granules. Production capacity. In 2018, the group had 8 varieties with sales revenue of over 100 million yuan, and had five trademarks of "Hayi Medicine", "Three Essences", "Guizhonggu", "Hutong", "Shiyitang" and "Shiyitang" and the use of "Shiyitang". right. Rentongtai, the listed company, mainly engaged in pharmaceutical wholesale and retail businesses, covering more than 10,000 product specifications, including Chinese patent medicines, Chinese herbal medicines, chemical preparations, antibiotics, biological products, biochemical drugs, medical devices and health products. There are 314 Renmin Tongtai Pharmaceutical chain stores with an annual turnover of 1.15 billion yuan. Its drug wholesale enterprises have carried out close cooperation with more than 1,000 medical institutions, more than 1,900 third terminals, and nearly 700 commercial customers in Heilongjiang Province. The market coverage rate of third-level hospitals is more than 95%, and the market coverage of second-level hospitals is more than 2-level hospitals. The rate is more than 90%. Its logistics and distribution center is the first modern medical flow center in Heilongjiang Province and a larger Northeast region. Its storage capacity is 400,000 boxes and an annual throughput capacity of 30 billion yuan. The Group also has a new drug research and development base covering an area of 40,000 square meters and a building area of 38,000 square meters - Harbin Pharmaceutical Group Technology Center, which has five research and developments, including biopharmaceuticals, chemical raw materials, chemical preparations, health foods, and quality testing and analysis. The platform has 25 invention authorized patents, and has obtained 6 production approvals and 17 clinical approvals in the past five years.
China Resources Pharmaceutical Holdings Co., Ltd.
China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-owned pharmaceutical listed company, mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. Up to now, China Resources Sanjiu has been included in the Shenzhen Component Index, CSI 500 and FTSE Russell Index. China Resources Sanjiu was predecessored by Shenzhen Southern Pharmaceutical Factory established in 1985. In 1999, five companies including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd. initiated the establishment of joint-stock companies; on March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code is 000999); in 2008, Officially entered China Resources Group; in 2010, the company's name was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.". China Resources Sanjiu’s main core business is positioned in the fields of CHC health consumer goods and prescription drugs, with a rich product line and a continuous enrichment of varieties. CHC's health consumer products business covers nearly 10 categories including colds, skin, gastrointestinal tract, cough relieving, orthopedics, pediatrics, dietary nutritional supplements, and its core products occupy a high market share; prescription drug business covers cardiovascular, anti-tumor, Digestive system, orthopedics, pediatrics, anti-infection and other treatment fields, it has the Xuesaitong Panax notoginseng series products, Shenfu injection, mitoxantrone hydrochloride injection for tracer, Huachansu tablets and injections, Yixuesheng Capsule , blood stasis, and sodium cefbiroster for injection have a high reputation in the medical end. In 2023, China Resources Sanjiu has 39 varieties with annual sales of over 100 million yuan, including "999 Cold Ling", "999 Dermatitis Ping", "Sanjiu Weitai", "999 Children's Cold Granules", and "999 Antiviral Oral Liquid ", "Qizhiwei Puer Granules", "Tianhe Gutong Tie Paste", "Yi Shanfu", "999 Aonuo Calcium Gluconate Zinc Oral Solution", "Xuesaitong Panax noto Series Products", "Kun Chinese Medicine Ginseng Lingjianpiwei Granules", "Afacalciferol Soft Capsules", "Sodium Hyaluronic Acid Injection" and so on have a leading position in related categories. The "999" brand enjoys high recognition in both the consumer and pharmaceutical industries. China Resources Sanjiu has always attached great importance to R&D and innovation. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu will focus on the strategic direction, continue to increase R&D investment, improve the construction of innovation systems and mechanisms, and enhance innovation and development capabilities. While increasing the cooperation between industry, academia and research, three research institutes of innovative drugs, traditional Chinese medicine and health drugs have been established and operated one after another; innovative cooperation with Shenzhen Bay Laboratory has been carried out in depth, and clinical related to the QBH-196 project of anti-tumor innovative drug QBH-196 project has been vigorously promoted. Research. In 2023, R&D investment was 889 million yuan, and the proportion of new product R&D investment increased. There are a total of 112 projects under development, mainly focusing on anti-tumor, orthopedics, skin, respiratory, anti-infection and other treatment fields, and in new product project establishment, product R&D, and product strength. Positive progress has been made in areas such as improvement. China Resources Sanjiu attaches great importance to the inheritance and innovation of traditional Chinese medicine, continues to deepen the full-process development system of traditional Chinese medicine, precipitates the research and development capabilities of traditional Chinese medicine, and focuses on the research on classic prescriptions of traditional Chinese medicine, standards of traditional Chinese medicine formula granules and medicinal materials resources. The classic prescription embodies the essence of traditional Chinese medicine. The company adheres to the research idea of "inheriting the essence, keeping the truth and innovation", focuses on the elderly, women, and children, covering the treatment fields of breathing, heart and brain, digestion, etc., and carries out "Medicinal Materials-Decoction-Benchmark Sample- Systematic research on compound preparations, and build a traceability system for the entire industrial chain of traditional Chinese medicine. China Resources Sanjiu continues to pay attention to high-quality domestic and foreign resources, and makes strategic mergers and acquisitions integration efforts. Among them, China Resources Sanjiu and its holding subsidiary Kunzi Pharmaceutical Group have good synergy in terms of brands, products, channels, etc., and the business integration is progressing smoothly. We empower each other in the development of the Panax notoginseng industry and the creation of the "Kunzi Chinese Medicine 1381" brand. Coordinated development will promote Kunming Pharmaceutical Group to become the first healthy stock in silver economics. Against the backdrop of the ever-changing environment of the pharmaceutical industry, China Resources Sanjiu embraces industry and market development opportunities, leads "high-quality development" with innovation, adheres to the dual-wheel drive of "brand + innovation", and focuses on innovation and research and development of high-quality pharmaceutical and health products and intelligent manufacturing , optimize business layout, strengthen brand and channel construction, increase innovation investment, actively explore innovative development models of industrial chains, build competitive advantages of the entire industrial chain of traditional Chinese medicine, improve operational quality and efficiency, and achieve steady improvement in operating performance and core capabilities. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu made solid progress on the road to becoming a leading enterprise in the industry, benchmarking against world-class enterprises, improving business layout, expanding its core business into the entire field of self-diagnosis and treatment, developing business focus on pipelines, and as the core Business empowerment to form a business model with "deep roots and lush leaves". Looking to the future, China Resources Sanjiu will always keep in mind its original mission and work hard to work hard. Under the mission of "caring for public health and creating a better life together", we will forge ahead to the goal of "leader of the mass medical and health industry" and serve Every member of the Chinese family.
China Resources Pharmaceutical Holdings Co., Ltd.
China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-owned pharmaceutical listed company, mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. Up to now, China Resources Sanjiu has been included in the Shenzhen Component Index, CSI 500 and FTSE Russell Index. China Resources Sanjiu was predecessored by Shenzhen Southern Pharmaceutical Factory established in 1985. In 1999, five companies including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd. initiated the establishment of joint-stock companies; on March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code is 000999); in 2008, Officially entered China Resources Group; in 2010, the company's name was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.". China Resources Sanjiu’s main core business is positioned in the fields of CHC health consumer goods and prescription drugs, with a rich product line and a continuous enrichment of varieties. CHC's health consumer products business covers nearly 10 categories including colds, skin, gastrointestinal tract, cough relieving, orthopedics, pediatrics, dietary nutritional supplements, and its core products occupy a high market share; prescription drug business covers cardiovascular, anti-tumor, Digestive system, orthopedics, pediatrics, anti-infection and other treatment fields, it has the Xuesaitong Panax notoginseng series products, Shenfu injection, mitoxantrone hydrochloride injection for tracer, Huachansu tablets and injections, Yixuesheng Capsule , blood stasis, and sodium cefbiroster for injection have a high reputation in the medical end. In 2023, China Resources Sanjiu has 39 varieties with annual sales of over 100 million yuan, including "999 Cold Ling", "999 Dermatitis Ping", "Sanjiu Weitai", "999 Children's Cold Granules", and "999 Antiviral Oral Liquid ", "Qizhiwei Puer Granules", "Tianhe Gutong Tie Paste", "Yi Shanfu", "999 Aonuo Calcium Gluconate Zinc Oral Solution", "Xuesaitong Panax noto Series Products", "Kun Chinese Medicine Ginseng Lingjianpiwei Granules", "Afacalciferol Soft Capsules", "Sodium Hyaluronic Acid Injection" and so on have a leading position in related categories. The "999" brand enjoys high recognition in both the consumer and pharmaceutical industries. China Resources Sanjiu has always attached great importance to R&D and innovation. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu will focus on the strategic direction, continue to increase R&D investment, improve the construction of innovation systems and mechanisms, and enhance innovation and development capabilities. While increasing the cooperation between industry, academia and research, three research institutes of innovative drugs, traditional Chinese medicine and health drugs have been established and operated one after another; innovative cooperation with Shenzhen Bay Laboratory has been carried out in depth, and clinical related to the QBH-196 project of anti-tumor innovative drug QBH-196 project has been vigorously promoted. Research. In 2023, R&D investment was 889 million yuan, and the proportion of new product R&D investment increased. There are a total of 112 projects under development, mainly focusing on anti-tumor, orthopedics, skin, respiratory, anti-infection and other treatment fields, and in new product project establishment, product R&D, and product strength. Positive progress has been made in areas such as improvement. China Resources Sanjiu attaches great importance to the inheritance and innovation of traditional Chinese medicine, continues to deepen the full-process development system of traditional Chinese medicine, precipitates the research and development capabilities of traditional Chinese medicine, and focuses on the research on classic prescriptions of traditional Chinese medicine, standards of traditional Chinese medicine formula granules and medicinal materials resources. The classic prescription embodies the essence of traditional Chinese medicine. The company adheres to the research idea of "inheriting the essence, keeping the truth and innovation", focuses on the elderly, women, and children, covering the treatment fields of breathing, heart and brain, digestion, etc., and carries out "Medicinal Materials-Decoction-Benchmark Sample- Systematic research on compound preparations, and build a traceability system for the entire industrial chain of traditional Chinese medicine. China Resources Sanjiu continues to pay attention to high-quality domestic and foreign resources, and makes strategic mergers and acquisitions integration efforts. Among them, China Resources Sanjiu and its holding subsidiary Kunzi Pharmaceutical Group have good synergy in terms of brands, products, channels, etc., and the business integration is progressing smoothly. We empower each other in the development of the Panax notoginseng industry and the creation of the "Kunzi Chinese Medicine 1381" brand. Coordinated development will promote Kunming Pharmaceutical Group to become the first healthy stock in silver economics. Against the backdrop of the ever-changing environment of the pharmaceutical industry, China Resources Sanjiu embraces industry and market development opportunities, leads "high-quality development" with innovation, adheres to the dual-wheel drive of "brand + innovation", and focuses on innovation and research and development of high-quality pharmaceutical and health products and intelligent manufacturing , optimize business layout, strengthen brand and channel construction, increase innovation investment, actively explore innovative development models of industrial chains, build competitive advantages of the entire industrial chain of traditional Chinese medicine, improve operational quality and efficiency, and achieve steady improvement in operating performance and core capabilities. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu made solid progress on the road to becoming a leading enterprise in the industry, benchmarking against world-class enterprises, improving business layout, expanding its core business into the entire field of self-diagnosis and treatment, developing business focus on pipelines, and as the core Business empowerment to form a business model with "deep roots and lush leaves". Looking to the future, China Resources Sanjiu will always keep in mind its original mission and work hard to work hard. Under the mission of "caring for public health and creating a better life together", we will forge ahead to the goal of "leader of the mass medical and health industry" and serve Every member of the Chinese family.
